New Paper in Cell Highlights the Potential Role of TB-403 (Anti-PlGF) in the Treatment of Medulloblastoma, a Pediatric Brain Tumor
LEUVEN, Belgium, February 28, 2013 /PRNewswire/ –
ThromboGenics NV (Euronext Brussels: THR), and co-development partner BioInvent
International AB (OMXS: BINV), announce today the publication of a paper in the
prestigious journal Cell, highlighting the potential of TB-403 to improve the treatment of
medulloblastoma, the most common brain tumor in children.
The Cell publication highlights for the first time a new mechanism of action, showing
that PlGF plays a vital role in the brain and that its expression is required for the
growth and spread of medulloblastoma.
The novel positive findings in this paper provide evidence that could warrant further
development of TB-403 as one of the first targeted therapies to treat this childhood
cancer. TB-403 is a monoclonal antibody against placental growth factor (PlGF). PIGF is a
naturally occurring protein that belongs to the family of vascular endothelial growth
factors (VEGF) that promote the formation of blood vessels.
TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology
(VIB), where the therapeutic potential of anti-PlGF agents to treat cancer was first
developed by Prof. Peter Carmeliet at the University of Leuven, Belgium.
This Cell paper is reporting the findings of new pre-clinical research performed at
the Massachusetts General Hospital in Harvard (Boston), in collaboration with the team of
Prof Peter Carmeliet.
With an emerging ophthalmologic franchise, Thrombogenics is also evaluating the role
of TB-403 for ophthalmic indications.
ThromboGenics is an integrated biopharmaceutical company focused on developing and
commercializing innovative ophthalmic medicines. The Company’s lead product,
JETREA(R)(ocriplasmin), has been approved by the US FDA for the treatment of symptomatic
VMA and was launched in January 2013.
In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for
the commercialization of JETREA(R) outside the United States. Under this agreement,
ThromboGenics could receive up to a total of EUR375 million in up-front and milestone
payments. It will receive significant royalties from Alcon’s net sales of JETREA(R).
ThromboGenics and Alcon intend to share the costs equally of developing JETREA(R) for a
number of new vitreoretinal indications.
The JETREA European Marketing Authorisation Application is currently under review by
the European Medicines Agency. Following the positive CHMP recommendation, a final
decision by the European Commission on European approval is expected in the first half of
ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), formerly
referred to as TB-403, for the treatment of ophthalmic indications.
ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US)
and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under
the symbol THR. More information is available at http://www.thrombogenics.com.
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a
research-based pharmaceutical company focused on discovery and development of innovative
antibody-based drugs against cancer. The Company’s pipeline currently includes three
product candidates for the treatment of cancer.
The company’s competitive position is underpinned by n-CoDeR(R), a proprietary
antibody development platform. The scope and strength of this platform is also used to
develop antibody-based drugs in collaboration with partners who finance the development of
the new drug, and provide BioInvent the right to milestone payments and royalties on
sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and
Servier. More information is available at http://www.bioinvent.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such
forward-looking statements are based on current expectations, and, accordingly, entail and
are influenced by various risks and uncertainties. The Company therefore cannot provide
any assurance that such forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement, whether as a result of new
information, future events or any other reason. Additional information concerning risks
and uncertainties affecting the business and other factors that could cause actual results
to differ materially from any forward-looking statement is contained in the Company’s
This press release does not constitute an offer or invitation for the sale or purchase
of securities or assets of ThromboGenics in any jurisdiction. No securities of
ThromboGenics may be offered or sold within the United States without registration under
the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom,
and in accordance with any applicable U.S. state securities laws.
For further information please contact: ThromboGenics: Wouter Piepers, Global Head of Corporate Communications +32-16-75-13-10 / +32-478-33-56-32 email@example.com Dr. Patrik De Haes, CEO +32-16-75-13-10 Patrik.firstname.lastname@example.org Chris Buyse, CFO +32-16-75-13-10 Chris.email@example.com BioInvent International AB: Cristina Glad, D.Sc., President & CEO +46-(0)708-16-85-70 firstname.lastname@example.org Citigate Dewe Rogerson David Dible/ Nina Enegren/ Sita Shah Tel: +44-(0)20-7638-9571 email@example.com The Trout Group (US investor relations) Todd James/ Simon Harnest Tel: +1-646-378-2926 firstname.lastname@example.org
SOURCE ThromboGenics NV